Erratum: Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis (PLoS ONE (2015) 10:6 (e0127771) DOI: 10.1371/journal.pone.0127771);Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Donahoe, Michael ^a   Valentine, Vincent G ^b   Chien, Nydia ^a   Gibson, Kevin F ^a   Raval, Jay S ^c   Saul, Melissa ^a   Xue, Jianmin ^a   Zhang, Yingze ^a   Duncan, Steven R ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DIPHENHYDRAMINE; EPITHELIAL AUTOANTIBODY; GLUCOSE; IMMUNOGLOBULIN; MATRILYSIN; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; FIBROSING ALVEOLITIS; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE; LUNG GAS EXCHANGE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; RELAPSE; SURVIVAL TIME; TOTAL LUNG CAPACITY; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGY; LUNG; MORTALITY; PATHOLOGY; PLASMA EXCHANGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GLUCOCORTICOIDS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LUNG; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMA EXCHANGE; RITUXIMAB; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84939140106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133684     Document Type: Erratum

References (52)

1. ST PMID: 24032382
2. Kim DS. Acute exacerbations of idiopathic pulmonary fibrosis. Clin Chest Med 2012; 33:59-68. doi: 10.1016/j.ccm.2012.01.001 PMID: 22365246
3. Campbell DA, Poulter LW, Janossy G, du Bois RM. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985; 40:405-11. PMID: 3875162
4. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, et al. Cutting edge: non-proliferating mature immune cells form a novel type of organizing lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006; 176:5735-5739. PMID: 16670278
5. Nuovo GJ, Hagood JS, Magro CM, Chin N, Kapil R, Davis L, et al. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol 2012; 25:416-33. doi: 10.1038/modpathol.2011.166 PMID: 22037258
6. Dall Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S. Study of immune complexes in broncholaveolar lavage fluids. Respiration 1988; 54:36-41. PMID: 3231904
7. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000; 178:171-179. PMID: 10871435
8. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007; 179:2592-2599. PMID: 17675522
9. Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, et al. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 2006; 67:284-297. PMID: 16720208
10. Ogushi F, Tani K, Endo T, Tada H, Kawano T, Asano T, et al. Autoantibodies to IL-1 in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 2001; 48:181-189. PMID: 11694958
11. Kurosu K, Takiguchi Y, Okada O, Yumoto N, Sakao S, Tada Y, et al. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J Immunol 2008; 181:756-767. PMID: 18566442
12. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Idiopathic pulmonary fibrosis patients with antibodies to heat shock protein 70 have poor prognoses. Am J Resp Crit Care Med 2013; 187:768-775. doi: 10.1164/rccm.201203-0506OC PMID: 23262513
13. Taillé C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:759-766. doi: 10.1164/rccm.201001-0076OC PMID: 20935114
14. Wallace WHH, Howie SM. Upregulation of tenascin and TGF-β production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen. J Pathol 2001; 195:251-256 PMID: 11592106
15. Yang Y, Fujita J, Bandoh S, Ohtsuki Y, Yamadori I, Yoshinouchi T, et al. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin Exp Immunol 2002; 128:169-174. PMID: 11982605
16. Shum AK, Alimohammadi M, Tan CL, Cheng MH, Metzger TC, Law CS, et al. BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Sci Transl Med 2013; 5:1-10.
17. Vittal R, Mickler EA, Fisher AJ, Zhang C, Rothhaar K, Gu H, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis. PLoS One 2013; 8:e76451. doi: 10.1371/journal.pone.0076451 PMID: 24204629
18. Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of patients with idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2014; 189:966-974. doi: 10.1164/rccm.201309-1592OC PMID: 24628285
19. Xue J, Kass DJ, Bon JM, Vuga L, Tan J, Csizmadia E, et al. Plasma B-lymphocyte stimulator (BLyS) and B-cell differentiation in idiopathic pulmonary fibrosis. J Immunol 2013; 191:2089-2095. doi: 10.4049/jimmunol.1203476 PMID: 23872052
20. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015; 70:48-56. doi: 10.1136/thoraxjnl-2013-204596 PMID: 25217476
21. Francois A, Gombault A, Villeret B, Alsaleh G, Fanny M, Gasse P, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun 2015; 56:1-11. doi: 10.1016/j.jaut.2014.08.003 PMID: 25441030
22. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory disease. Nature Rev 2006; 6:205-211. PMID: 16498451
23. Browning JL. B cells move to center stage: novel opportunities for autoimmune disease treatment. Nat Rev 2006 5:564-575. PMID: 16816838
24. Corsiero E, Bombardieri M, Manzo A, Bugatti S, Uguccioni M, Pitzalis C. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012; 145:62-67. doi: 10.1016/j.imlet.2012.04.013 PMID: 22698185
25. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58:2257-67. doi: 10.1002/art.23667 PMID: 18668547
26. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS ONE 2010; 5:e11986. doi: 10.1371/journal.pone.0011986 PMID: 20700489
27. Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheum 2010; 37:45-52. doi: 10.3899/jrheum.090450 PMID: 19955043
28. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 2009; 120:2012-2024. doi: 10.1161/CIRCULATIONAHA.108.771170 PMID: 19917895
29. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arth Rheum 2008; 58: 1762-1773.
30. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009; 11: R84. doi: 10.1186/ar2718 PMID: 19500335
31. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066-1073. doi: 10.1172/JCI38010 PMID: 19411764
32. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol 2006; 18:263-275. PMID: 16914324
33. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthrtitis Res Ther 2010; 12: R48. doi: 10.1186/ar2959 PMID: 20302641
34. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47:434-44. PMID: 12209492
35. Erickson SB, Kurtz SB, Donadio JV, Holley KE, Wilson CB, Pineda AA. Use of combined plasmapharesis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin Proc 1979; 54:714-720. PMID: 491763
36. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48:968-971. doi: 10.1093/rheumatology/kep157 PMID: 19531628
37. Borie R, Debray MP, Laine C, Aubier M, Crestani B. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33,1503-1506. doi: 10.1183/09031936.00160908 PMID: 19483052
38. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Resp J 2012; 40:641-648. doi: 10.1183/09031936.00163911 PMID: 22282550
39. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232. doi: 10.1056/NEJMoa0909905 PMID: 20647199
40. Orlin JB, Berkman EM. Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. Blood 1980; 56:1055-1060. PMID: 6159932
41. Reverberi R, Reverberi L. Removal kinetics of therapeutic apheresis. Blood Transfus 2007; 5:164-174. doi: 10.2450/2007.0032-07 PMID: 19204770
42. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185:67-76. doi: 10.1164/rccm.201101-0058OC PMID: 22016448
43. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012; 32:1119-1136. PMID: 22493341
44. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, et al. The HLA Class II allele DRB1∗1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 2011; 6: e14715. doi: 10.1371/journal.pone.0014715 PMID: 21373184
45. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One. 2010; 5:e8959. doi: 10.1371/journal.pone.0008959 PMID: 20126467
46. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, et al. Peripheral blood mononuclear cell gene expression profiles may predict poor outcome in idiopathic pulmonary fibrosis. Sci Translat 2013; 5:205ra136.
47. Lee SJ, Kavanaugh A. Autoimmunity, vasculitis and autoantibodies. J Allerg Clin Immunol 2006; 117: S445-450. PMID: 16455344
48. Pordeus V, Szyper-Kravitz M, Levy RA, Vaz NM, Shoenfeld Y. Infections and autoimmunity: a panorama. Clinic Rev Allerg Immunol 2008; 34:283-299.
49. Lindstrom TM, Robinson WH. Rheumatoid arthritis: a role for immunosenescence? J Am Geriatr Soc. 2010: 1565-1575. doi: 10.1111/j.1532-5415.2010.02965.x PMID: 20942872
50. Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells - a reflection of T cell differentiation, cell senescence and host environment. Semin Immunol. 2012; 24:365-372. doi: 10.1016/j.smim.2012.04.003 PMID: 22560928
51. Nydegger UE, Sturzenegger M. Treatment of autoimmune disease: synergy between plasma exchange and intravenous immunoglobulin. Therap Apher 2001; 5:186-192.
52. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Eng J Med 2012; 167:2015-2025.